Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.57 |
| ▸ | PDE4A | P27815 | 3/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.57 |
| ▸ | PPARA | Q07869 | 6/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 5/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743334 | 0.94 | ACHE (0.55) | PDE4BPDE4APDE4CPDE4DPPARA | |
| SCHEMBL3736174 | 0.94 | ACHE (0.55) | PDE4BPDE4APDE4CPDE4DPPARA | |
| SCHEMBL3743898 | 0.89 | PDE4D (0.73) | PDE4BPDE4APDE4CPDE4DPPARA | |
| SCHEMBL3735519 | 0.84 | ACHE (0.65) | PDE4BPDE4APDE4CPDE4DPPARA | |
| SCHEMBL3743578 | 0.81 | PPARA (0.49) | PDE4BPDE4APDE4CPDE4DPPARA | |
| SCHEMBL3740036 | 0.78 | ACHE (0.52) | PPARAPPARGACHEPPARDFFAR1 | |
| SCHEMBL4431572 | 0.77 | RXRA (0.52) | PPARAPPARDRXRARXRBRXRG | |
| SCHEMBL3729768 | 0.77 | PDPK1 (0.46) | PPARAPPARGPPARDFFAR1PDPK1 | |
| SCHEMBL3743590 | 0.77 | PDE4A (0.43) | PDE4BPDE4APDE4CPDE4DPPARA | |
| SCHEMBL28658865 | 0.75 | NPC1 (0.66) | PDE4BMMP1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | PDE4B 2627/4885PDE4A 2570/4885PDE4C 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.